Digenic Alport syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:653722
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Digenic Alport syndrome (Orphanet code 653722) is a rare hereditary kidney disease caused by pathogenic variants in two different genes encoding type IV collagen, typically involving combinations of COL4A3, COL4A4, and/or COL4A5. Unlike the classic forms of Alport syndrome that follow a single-gene inheritance pattern (X-linked, autosomal recessive, or autosomal dominant), digenic Alport syndrome results from the combined effect of heterozygous variants in two of these collagen IV genes, which together produce a more severe phenotype than would be expected from either variant alone. This digenic mechanism helps explain some cases where disease severity does not match predictions based on a single identified variant. The disease primarily affects the kidneys, inner ears, and eyes. The hallmark feature is progressive glomerular disease leading to hematuria (blood in the urine), proteinuria (protein in the urine), and progressive decline in kidney function that can ultimately lead to end-stage kidney disease (ESKD). Sensorineural hearing loss, particularly at high frequencies, is a common associated feature. Ocular abnormalities, including anterior lenticonus and retinal flecks, may also occur. The underlying pathology involves abnormal type IV collagen in the glomerular basement membrane, cochlea, and lens capsule, leading to structural and functional deterioration of these tissues. There is currently no cure for digenic Alport syndrome. Treatment focuses on slowing the progression of kidney disease, primarily through the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which reduce proteinuria and delay the onset of end-stage kidney disease. Early initiation of these renoprotective therapies is recommended. Patients who progress to ESKD require renal replacement therapy, including dialysis or kidney transplantation. Hearing aids may be needed for sensorineural hearing loss, and ophthalmologic monitoring is advised for ocular complications. Genetic counseling is important for affected families given the complex inheritance pattern.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood to adulthood

Can begin any time from childhood through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Digenic Alport syndrome.

View clinical trials →

No actively recruiting trials found for Digenic Alport syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Digenic Alport syndrome community →

No specialists are currently listed for Digenic Alport syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Digenic Alport syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Digenic Alport syndromeForum →

No community posts yet. Be the first to share your experience with Digenic Alport syndrome.

Start the conversation →

Latest news about Digenic Alport syndrome

No recent news articles for Digenic Alport syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Digenic Alport syndrome

What is Digenic Alport syndrome?

Digenic Alport syndrome (Orphanet code 653722) is a rare hereditary kidney disease caused by pathogenic variants in two different genes encoding type IV collagen, typically involving combinations of COL4A3, COL4A4, and/or COL4A5. Unlike the classic forms of Alport syndrome that follow a single-gene inheritance pattern (X-linked, autosomal recessive, or autosomal dominant), digenic Alport syndrome results from the combined effect of heterozygous variants in two of these collagen IV genes, which together produce a more severe phenotype than would be expected from either variant alone. This digen

At what age does Digenic Alport syndrome typically begin?

Typical onset of Digenic Alport syndrome is childhood to adulthood. Age of onset can vary across affected individuals.